- T
Triplet Therapeutics
- Amy Lurier
Amy has over 35 years in Recruitment and Talent Acquisition in the biotech startup arena. Prior to joining Triplet Therapeutics, Inc., Amy owned a search firm and was involved in a multitude of early stage start-ups including such companies as Akrevia Therapeutics, Korro Bio and Intellia. Prior to becoming a search professional, Amy was Director of Technology at a start-up instrumentation company in Boston. She holds a degree in Medicinal and Organic Chemistry from the University of Massachusetts, Boston.
Org chart
Teams
Offices
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.
